Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash from Financing Activities: 2010-2025

Historic Cash from Financing Activities for Sunshine Biopharma (SBFM) over the last 11 years, with Sep 2025 value amounting to $75,536.

  • Sunshine Biopharma's Cash from Financing Activities fell 96.13% to $75,536 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 17.86%. This contributed to the annual value of $9.3 million for FY2024, which is 171.18% up from last year.
  • As of Q3 2025, Sunshine Biopharma's Cash from Financing Activities stood at $75,536, which was down 97.91% from $3.6 million recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Cash from Financing Activities registered a high of $29.1 million during Q2 2022, and its lowest value of -$2.1 million during Q4 2022.
  • For the 3-year period, Sunshine Biopharma's Cash from Financing Activities averaged around $1.5 million, with its median value being $338,137 (2025).
  • Per our database at Business Quant, Sunshine Biopharma's Cash from Financing Activities slumped by 8,758.42% in 2022 and then spiked by 12,730.71% in 2025.
  • Quarterly analysis of 5 years shows Sunshine Biopharma's Cash from Financing Activities stood at -$23,664 in 2021, then slumped by 8,758.42% to -$2.1 million in 2022, then skyrocketed by 98.54% to -$30,519 in 2023, then skyrocketed by 6,542.34% to $2.0 million in 2024, then slumped by 96.13% to $75,536 in 2025.
  • Its last three reported values are $75,536 in Q3 2025, $3.6 million for Q2 2025, and $338,137 during Q1 2025.